PHYX-001

PHYX-001 is a potassium channel modulator developed for central nervous system (CNS) diseases. Its mechanism of action is similar to that of XEN1101 and BHV-7000, both of which are known as next-generation potassium channel modulators with anticonvulsant properties. The drug was initially developed by Phytanix and later became part of the pipeline following the merger with Protagenic Therapeutics. PHYX-001 is being explored for indications within nervous system diseases, including potential applications in obesity and metabolic dysfunction, though its highest phase of development remains unknown as of June 2025[1][2][3][4].